Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P16499
UPID:
PDE6A_HUMAN
Alternative names:
PDE V-B1
Alternative UPACC:
P16499; Q0P638
Background:
The Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha, also known as PDE V-B1, plays a crucial role in the visual signal transduction pathway. It is responsible for the hydrolysis of 3',5'-cyclic GMP, a process vital for the transmission and amplification of visual signals.
Therapeutic significance:
Given its pivotal role in retinal function, PDE V-B1 is directly implicated in Retinitis pigmentosa 43, a progressive retinal dystrophy. Understanding the role of PDE V-B1 could open doors to potential therapeutic strategies for this debilitating condition.